Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

FCR-I/iven combination for CLL: «Cheap but fierce»

View Full Paper
Ask AI
Bookmark
Share

Authors

VDVitaly S. DubovЕЗЕ. Е. ЗвонковOSOlga Shtetsova

Discussion

Loading...

Member takes

Overview

Multicenter trial finds FCR-ibrutinib with/without venetoclax achieves 100% response rates in CLL, highlighting improved outcomes.

Key Points

  • Evaluate the efficacy and safety of FCR with ibrutinib with/without venetoclax in untreated CLL patients.
  • Previously untreated CLL patients received 3-6 cycles of FCR with ibrutinib or ibrutinib and venetoclax.
  • Treatment assessed for minimal residual disease using multicolor flow cytometry after therapy completion.
  • Patients underwent PET/CT scans for evaluation.
  • Overall response rate was 100% among treated patients.
  • 100% of patients achieved complete remission with negative minimal residual disease.
  • Follow-up median showed no significant difference in progression-free survival rates among subgroups.

Cite This Study

Dubov et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d205https://doi.org/10.1182/blood-2025-7425
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia2025 · 32 citations
  2. 2Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.2024 · 6 citations
  3. 3Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study2026
  4. 4Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi‐Center Study2026
  5. 5MRD-guided ibrutinib plus venetoclax improves outcomes in CLL patients with TP53, ATM, or NOTCH1 aberrations compared to ibrutinib and FCR: Results from the Phase III NCRI FLAIR trial2025 · 1 citations